Editorial, Trade Groups Offer Perspective On Null Chondroitin Meta-Analysis
This article was originally published in The Tan Sheet
Executive Summary
Patients should continue taking chondroitin sulfate for osteoarthritis if they perceive a benefit, despite a recent study that found a null effect, according to an accompanying editorial in the April 17 Annals of Internal Medicine